Obstructive Sleep Apnea - Competitive Landscape and Clinical Trial Analysis, 2026

DelveInsight's, "Obstructive Sleep Apnea - Competitive Landscape and Clinical Trial Analysis, 2026," report provides comprehensive insights about 18+ companies and 20+ drugs in Obstructive Sleep Apnea Competitive landscape. It covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered:

• Global coverage

Obstructive Sleep Apnea: Understanding

Obstructive Sleep Apnea: Overview

Obstructive sleep apnea (OSA) is a common sleep-related breathing disorder characterized by repeated partial or complete blockage of the upper airway during sleep. These episodes cause apnea or hypopnea, resulting in intermittent oxygen desaturation, sleep fragmentation, and repeated arousals. OSA is associated with excessive daytime sleepiness, fatigue, impaired cognition, and an increased risk of cardiovascular and metabolic complications.

OSA results from a combination of upper-airway anatomy and physiological factors that increase airway collapsibility during sleep. Major risk factors include obesity, older age, male sex, increased neck circumference, craniofacial abnormalities, menopause, family history, smoking, and nasal congestion. Excess fat around the neck can narrow the upper airway and increase its tendency to collapse during sleep.

During sleep, reduced activity of the upper-airway muscles can cause the airway to narrow or collapse in susceptible individuals. This leads to repeated episodes of apnea or hypopnea, followed by oxygen desaturation, carbon dioxide accumulation, and brief arousals that restore airway patency. Recurrent intermittent hypoxia and sleep fragmentation can increase sympathetic activity, oxidative stress, and inflammation, contributing to cardiovascular and metabolic complications.

Diagnosis involves clinical assessment followed by objective sleep testing. Overnight polysomnography (PSG) is the standard diagnostic test and measures airflow, respiratory effort, oxygen saturation, brain activity, and other physiological parameters during sleep. The apnea-hypopnea index (AHI) is used to assess disease severity: 5-<15 events/hour indicates mild OSA, 15-<30 indicates moderate OSA, and >=30 indicates severe OSA. Home sleep apnea testing may also be used in selected patients.

Treatment aims to maintain airway patency, reduce respiratory events, and improve symptoms and quality of life. Continuous positive airway pressure (CPAP) is the main treatment, particularly for moderate-to-severe OSA, as it prevents airway collapse during sleep. Other options include weight management, mandibular advancement devices, BiPAP, and surgical interventions, depending on disease severity, anatomy, comorbidities, and treatment tolerance.

Report Highlights:

• In July 2026, Apnimed, Inc. announced that the U.S. Food and Drug Administration ("FDA") has accepted for review the New Drug Application filing of AD109 (aroxybutynin 2.3 mg/atomoxetine 75 mg) for the treatment of adults with obstructive sleep apnea. The FDA has assigned a Prescription Drug User Fee Act ("PDUFA") target action date of February 28, 2027.
• In June 2026, Incannex Healthcare Inc. announced that the United States Patent and Trademark Office (USPTO) has granted a key patent titled "Compositions and Methods of Treatment for Obstructive Sleep Apnea."
• In May 2026, Apnimed Inc. announced the simultaneous publication of two peer-reviewed articles on AD109 (aroxybutynin 2.5 mg/atomoxetine 75 mg), an investigational, once-daily oral pill taken at bedtime designed to improve oxygenation and target the neuromuscular root cause of obstructive sleep apnea (OSA). The Phase III SynAIRgy trial results were published in the American Journal of Respiratory and Critical Care Medicine (AJRCCM), alongside a companion mechanistic review article in the American Journal of Respiratory Cell and Molecular Biology (AJRCMB) that highlighted AD109's neuromuscular mechanism of action and the biological rationale that directly informed the design and success of the Phase III program.
• In December 2025, Incannex Healthcare Inc. announced that the US Food and Drug Administration (FDA) has granted Fast Track designation for IHL-42X, the Company's oral fixed-dose combination product candidate for the treatment of obstructive sleep apnea (OSA).
• In May 2025, Mosanna Therapeutics, announced the close of USD 80 million in Series A funding. The company is developing an easy-to-use nighttime nasal spray to treat obstructive sleep apnea that will help restore the body's natural airway control. The financing was led by Pivotal bioVenture Partners and EQT Life Sciences, along with Forbion, Broadview Ventures and Norwest as co-lead investors. Returning investors included founding investor Forty51 Ventures, as well as Supermoon Capital and High-Tech Grunderfonds (HTGF). The company has also announced that this series A funding to advance MOS118 through Phase II clinical trials.
• In January 2025, Mineralys Therapeutics announced that the U.S. Food and Drug Administration (FDA) has cleared the Company's Investigational New Drug (IND) Application for a Phase II clinical trial to evaluate the effect of lorundrostat in the treatment of subjects with moderate-to-severe obstructive sleep apnea (OSA) and hypertension.

Obstructive Sleep Apnea: Company and Product Profiles (Marketed Therapies)

1. Company Overview: Eli Lilly and Company

Eli Lilly and Company is a global pharmaceutical company headquartered in Indianapolis, Indiana, U.S., founded in 1876. The company focuses on discovering, developing, manufacturing, and delivering medicines aimed at addressing major health challenges. Lilly conducts research and clinical development globally and has a portfolio spanning areas including diabetes, obesity, oncology, immunology, neuroscience, and other diseases. The company's mission is to create medicines that make life better for people around the world, with innovation and pharmaceutical research at the core of its activities.

Product Description: Zepbound

Zepbound (Tirzepatide) is a dual GIP (glucose-dependent insulinotropic polypeptide) and GLP-1 (glucagon-like peptide-1) receptor agonist developed by Eli Lilly and Company. It acts by activating GIP and GLP-1 receptors, which helps reduce appetite and food intake, leading to significant body-weight reduction. For obstructive sleep apnea (OSA), its therapeutic effect is primarily associated with weight loss, which can reduce upper-airway obstruction during sleep and consequently decrease the frequency of apnea and hypopnea events. The U.S. FDA approved tirzepatide in December 2024 for the treatment of moderate-to-severe OSA in adults with obesity, making it the first FDA-approved medication specifically for OSA.

Obstructive Sleep Apnea: Company and Product Profiles (Pipeline Therapies)

1. Company Overview: Apnimed

Apnimed is a privately held late stage clinical pharmaceutical company dedicated to the discovery, development and commercialization of novel oral therapies that address the neurobiology of sleep-related breathing diseases. The company believes the introduction of once-nightly oral drugs has the potential to expand diagnosis and the reach of treatment for people with OSA. Also the company believes that people with OSA would benefit from having multiple drugs with differing mechanisms to more fully address the heterogeneity of OSA's disease pathophysiology. Apnimed envisions a new era where novel oral therapies simplify intervention, expand the reach of diagnosis and treatment, and help more people get the oxygen and restorative sleep needed to thrive.

Product Description: AD109

AD109 is investigational and is designed to be the first potential pharmacological treatment to improve oxygenation during sleep and target the neuromuscular root cause of upper airway collapse in people with OSA. It is a potentially first-in-class combination of aroxybutynin, a novel antimuscarinic, and atomoxetine, a selective norepinephrine reuptake inhibitor. AD109 is a once-daily oral pill taken at bedtime that is designed to lower the complexity of intervention and may help more people benefit from effective, restorative sleep. In a disease treatment landscape characterized by complex and invasive treatment options, AD109, if approved, may offer a convenient oral solution to help improve oxygenation and health for people living with OSA. The US Food and Drug Administration (FDA) assigned a Prescription Drug User Fee Act (PDUFA) target action date of February 28, 2027, for AD109 (aroxybutynin/atomoxetine), an investigational once-nightly oral pill developed by Apnimed to treat adults with obstructive sleep apnea.

2. Company Overview: Eli Lilly and Company

Eli Lilly and Company is a global medicine company headquartered in Indianapolis, Indiana, founded in 1876. The company focuses on discovering, developing, and delivering medicines intended to address significant health challenges and improve patient's lives. Lilly conducts research across multiple therapeutic areas and has a global presence, with clinical research conducted in more than 55 countries. Its research and development efforts are supported by a broad portfolio of innovative medicines and continued investment in the discovery and development of new treatments.

Product Description: Orforglipron

Orforglipron is a once-daily, oral, small-molecule (non-peptide) glucagon-like peptide-1 (GLP-1) receptor agonist developed by Eli Lilly. It acts by activating GLP-1 receptors, which helps reduce appetite and food intake, thereby supporting body-weight reduction. As a GLP-1 receptor agonist, it also improves glucose regulation by enhancing glucose-dependent insulin secretion and reducing glucagon secretion. Unlike injectable peptide-based GLP-1 therapies, orforglipron is an oral small molecule that can be taken without restrictions on food or water intake. Orforglipron was discovered by Chugai Pharmaceutical Co., Ltd. and licensed by Lilly in 2018. Currently, the drug is being evaluated in the Phase III stage of its development for the treatment of Sleep Apnea.

3. Company Overview: Incannex Healthcare

Incannex is leading the way in developing combination medicines that target the underlying biological pathways associated with chronic conditions, including obstructive sleep apnea, rheumatoid arthritis and generalized anxiety disorder. The company is advancing three clinical-stage product candidates based on evidence-based innovation and supported by streamlined operations. The company is advancing many clinical-stage product which include Incannex's lead clinical program, IHL-42X, is an oral fixed-dose combination of dronabinol and acetazolamide designed to target underlying mechanisms and act synergistically in the treatment of obstructive sleep apnea. Incannex is committed to advancing therapies that address multiple biological pathways with the goal of improving patient outcomes and creating long-term shareholder value.

Product Description: IHL-42X

IHL-42X is an oral fixed-dose combination therapy of dronabinol and acetazolamide designed to act synergistically by targeting two physiological mechanisms involved in OSA. Dronabinol, a synthetic form of delta-9-tetrahydrocannabinol (THC), acts on cannabinoid receptors and is intended to stimulate upper-airway dilation, thereby helping reduce airway obstruction during sleep. Acetazolamide, a carbonic anhydrase inhibitor, induces a mild metabolic acidosis, which signals increased carbon dioxide levels to the body and stimulates ventilation. By combining these mechanisms, IHL-42X is intended to address both upper-airway dysfunction and ventilatory control instability, thereby reducing the frequency of apneas and hypopneas, measured by the Apnea-Hypopnea Index (AHI). Currently the drug is in Phase II/III stage of its development for the treatment of Obstructive Sleep Apnea.

4. Company Overview: Mosanna Therapeutics

Mosanna Therapeutics is focused on developing a pharmaceutical approach to obstructive sleep apnea (OSA), with the goal of shifting treatment from external, mechanical intervention toward restoring the body's natural airway control during sleep. The company is developing an easy-to-use nighttime nasal spray designed to help restore the body's natural airway control and reactivate the upper airway muscles to keep the airway open. Mosanna describes its approach as working with the body's natural physiology rather than mechanically forcing the airway open.

Product Description: MOS118

MOS118 is an investigational intranasal small-molecule therapy developed by Mosanna Therapeutics for the treatment of obstructive Sleep Apnea (OSA). Administered as a bedtime nasal spray, MOS118 is designed to restore the body's natural upper airway reflexes by temporarily modulating the neuromuscular control of the throat and upper airway muscles, thereby reducing airway collapse during sleep and maintaining airway patency. Unlike mechanical therapies such as CPAP, MOS118 targets the underlying neuromuscular dysfunction associated with OSA through a non-invasive pharmacological approach. Currently, the drug is being evaluated in the Phase I stage of its development for the treatment of Sleep Apnea.

Obstructive Sleep Apnea Analytical Perspective by DelveInsight

• In-depth Commercial Assessment: Obstructive Sleep Apnea Collaboration Analysis by Companies

The Report provides in-depth commercial assessment of drugs that have been included, which comprises collaboration, agreement, licensing and acquisition - deals values trends. The sub-segmentation is described in the report which provide company-company collaboration (licensing/partnering), company academic collaboration and acquisition analysis in tabulated form.

• Obstructive Sleep Apnea Competitive Landscape

The report comprises of comparative assessment of Companies (by therapy, development stage, and technology).

Obstructive Sleep Apnea Report Assessment

• Company Analysis
• Therapeutic Assessment
• Pipeline Assessment
• Inactive drugs assessment
• Unmet Needs

Obstructive Sleep Apnea Clinical Trial Assessment

• Clinical Trial Analysis
• Clinical Trial Design Analysis
• Sponsor and Geographical Analysis
• Obstructive Sleep Apnea Clinical Trial Analysis

The report comprises of comparative assessment of clinical trial analysis (by status, development stage, therapy area, enrolled participants by age, study completion year, end point status).

• Obstructive Sleep Apnea Clinical Trial Design Analysis

The report comprises of comparative assessment of clinical trial design analysis (by allocation, interventional model, enrolled participants by status, masking).

• Sponsor and Geographical Analysis

The report comprises of comparative assessment of sponsor and geographical analysis (by top sponsors, developmental stage, clinical trials sponsored by countries, therapies by countries).

Key Questions:

Current Treatment Scenario and Emerging Therapies:

• How many companies are developing Obstructive Sleep Apnea drugs?
• How many Obstructive Sleep Apnea drugs are developed by each company?
• How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Obstructive Sleep Apnea?
• What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the Obstructive Sleep Apnea therapeutics?
• What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for Obstructive Sleep Apnea and their status?
• What are the key designations that have been granted to the emerging and approved drugs?

Key Players

• Eli Lilly and Company
• Apnimed
• Amgen
• Mosanna Therapeutics
• Mineralys Therapeutics Inc.
• Shionogi-Apnimed Sleep Science, LLC
• Incannex Healthcare Ltd
• Novo Nordisk
• Gan & lee pharmaceuticals
• Hangzhou Sciwind Biosciences Co., Ltd.
• Hengrui Pharma
• Kailera Therapeutics

Key Products

• Zepbound
• AD109
• Eloralintide
• Orforglipron
• Maridebart cafraglutide
• MOS118
• Lorundrostat
• SASS-001
• SASS-002 (sulthiame)
• IHL42X
• NNC0487-0111
• GZR18
• XW003
• Ribupatide injection (HRS9531, known as KAI-9531 outside Greater China)